Abstracts tagged "Fibromyalgia and vaccines"

Abstract Number: 41 • 2016 ACR/ARHP Annual Meeting
Human Papilloma Virus Vaccination, Fibromyalgia and Dysautonomia
Manuel Martínez-Lavín¹, Paola-Kinara Reyes-Loyola² and Laura-Aline Martinez-Martinez³, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Rheumatology, National Institute of Cardiology, Mexico, Mexico, ³Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, TX, Mexico
Background/Purpose: In a questionnaire-based case series, we described the clinical features of 45 patients who had the onset of a chronic illness soon after HPV…
Abstract Number: 1098 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Influenza Vaccination In Patients Suffering From Fibromyalgia
Jacob N. Ablin¹, Valerie Aloush¹, Ayelet Brill², Mark Berman³, Merav Barzilai⁴, Dan Caspi¹, Michal Mandelboim⁵, David Levartovsky⁶, Ari Polachek⁷, Yonatan Wolman¹, Daphna Paran⁸, Michael Barkagan⁴ and Ori Elkayam⁹, ¹Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Internal Medicine F, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁴Internal Medicine 6, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵Central Virology Laboratory, Sheba Medical Center, Ramat Gan, Israel, ⁶Rheumatology, Tel Aviv Medical Ctr, Tel Aviv, Israel, ⁷Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, ⁸Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, ⁹Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel
Background/Purpose: Fibromyalgia syndrome (FMS) is considered to result from exposure of a genetically susceptible individual to various "triggers" including physical trauma, stress etc. Viral infections…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].